Friday, February 12, 2016

Titan Medical prices overnight offering

Titan Medical prices overnight offering

February 5, 2016 by · Leave a Comment 

Tweet Titan Medical (OTCQX:TITXF; TSX:TMD) has priced an overnight marketed offering of equity securities, issuing up to 8,888,889 units at a price of 90 cents each for gross proceeds of about $8-million. Each unit consists of one common share of the company and one warrant. Each warrant is exercisable at a price of $1 to […]

Microbix developing program to combat Zika virus

Microbix developing program to combat Zika virus

February 5, 2016 by · Leave a Comment 

Tweet Microbix Biosystems (TSX:MBX) has made plans to develop and introduce new products for use in diagnostic tests and vaccine research in response to the emergent Zika virus, which is spreading throughout the Americas and is being characterized as a crisis by health authorities. The Zika virus is a member of the flavivirus family, which […]

Knight to sublicense Titan Pharma’s Probuphine in Canada

Knight to sublicense Titan Pharma’s Probuphine in Canada

February 1, 2016 by · Leave a Comment 

Tweet Titan Pharmaceuticals’ (NASDAQ:TTNP) development and marketing partner, closely-held Braeburn Pharmaceuticals, and Knight Therapeutics (TSX:GUD) have entered into an agreement, giving Knight exclusive rights to commercialize Titan’s Probuphine in Canada. Probuphine is an investigational subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment, promoting patient compliance and retention, as well […]

Transition Therapeutics reports TT401 trial results

Transition Therapeutics reports TT401 trial results

February 1, 2016 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes. TT401 is a once-weekly administered oxyntomodulin analog, with dual GLP-1 and glucagon agonist activity. TT401 development collaborator, Eli Lilly, performed the Phase 2 study, enrolling 420 Type 2 diabetes subjects […]

TearLab estimates Q4 revenue rose 28%

TearLab estimates Q4 revenue rose 28%

February 1, 2016 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) expects to report revenue of approximately $6.8-million for the fourth quarter of 2015, up about 28% from the same quarter in 2014. In addition, TearLab estimated that a net total of 258 TearLab Osmolality Systems were added in the fourth quarter of 2015, of which 200 were under the company’s new […]

Novadaq Q4 revenue to jump about 54%

Novadaq Q4 revenue to jump about 54%

January 12, 2016 by · Leave a Comment 

Tweet Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has released preliminary unaudited revenue for the fourth quarter of 2015 of approximately $20-million, reflecting increases of about 54% from $13-million in the 2014 fourth quarter and 18% sequentially over $17-million in the third quarter last year. For all of 2015, the company anticipates total revenues to be approximately $63.8-million, […]

JMP resumes coverage of Novadaq at outperform

JMP resumes coverage of Novadaq at outperform

January 6, 2016 by · Leave a Comment 

Tweet JMP Securities has resumed coverage of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) with a “market outperform” rating and $16 price target. The stock closed at $13.50 on Tuesday. “Novadaq was once highly regarded within the small cap MedTech world, but its shares were driven down from historical highs by what we believe were overblown concerns around […]

Microbix posts gains in fiscal 2015 revenue, net income

Microbix posts gains in fiscal 2015 revenue, net income

December 31, 2015 by · Leave a Comment 

Tweet Microbix Biosystems (TSX:MBX) has reported revenue of $8.9-million for the fiscal year ended last Sept. 30, up 6% from $8.4-million a year earlier. Net Income was $613,984 in fiscal 2015, compared with $168,979 in 2014, an increase of 263%. “The year was also highlighted by major investments across the company in support of our […]

Wedbush ups Novadaq price target to $17

Wedbush ups Novadaq price target to $17

November 12, 2015 by · Leave a Comment 

Tweet Wedbush Securities has raised its price target for “outperform-rated” Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to $17 from $15. The stock finished at $11.16 on Wednesday. “Novadaq is the leader in the rapidly growing intraoperative fluorescence imaging market, and we believe the company’s extensive research and development in this field, plus cumulative clinical/commercial experience, should keep […]

TearLab Q3 revenue climbs 27%

TearLab Q3 revenue climbs 27%

November 5, 2015 by · Leave a Comment 

Tweet Third quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 27% to $6.6-million from $5.2-million a year ago. A net total of 228 TearLab systems were added in the third quarter. “We delivered a strong growth quarter both sequentially and compared with the prior year by expanding our device base and continuing to establish the clinical […]

Next Page »

Email Newsletters with Constant Contact
Google+